This study demonstrates that cilofexor improves cholestatic liver injury and decreases hepatic fibrosis, a key driver of liver failure in PSC, and to a certain extent hepatic inflammation, in the Mdr2-/- mouse model of sclerosing cholangitis. The gene discussed is ABCB4; the disease is sclerosing cholangitis.